In celebration of his incredible accomplishments as a lymphoma researcher and doctor, his years of contributions to the lymphoma community, and his support of the Lymphoma Research Foundation (LRF), LRF will honor Anas Younes, MD with its Distinguished Leadership Award…
On July 10, the Lymphoma Research Foundation (LRF) is participating in a day of action in support of the Clinical Treatment Act, a bill that would provide Medicaid coverage of the routine care costs of clinical trials participation. Here is…
The Nation’s Premier Lymphoma-Specific Research Organization Also Adds Two Experts to Industry-Leading SAB NEW YORK (July 1, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the…
On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after at least two prior…
Largest Wine and Spirits Distributor in North America Receives LRF Award for Outstanding Commitment to Foundation’s Mission NEW YORK (June 7, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research…
Chicago Philanthropic Community Supports LRF’s Mission to Eradicate Lymphoma and Serve Those Impacted by this Blood Cancer CHICAGO – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma…
In a study funded in part by the Lymphoma Research Foundation, researchers find the loss of specific protein amplification and transcriptional reprogramming contribute to resistance to venetoclax for patients with B-cell lymphomas Researchers from Moffitt Cancer Center and Dana-Farber Cancer…
On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular…
On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. The approval was…
New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and Genentech, Inc.) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic…